Patient who cannot receive FOLFIRI

More than 1 prior chemotherapy regimens for metastatic colorectal cancer

Pregnant, intent to be pregnant, or nursing female patient

Patient with any chronic inflammatory bowel disease

Patient treated for a cancer other than colorectal cancer within five years before enrollment

Patient with an hepatic involvement \> 50%

Patient with active central nervous system (CNS) metastasis or history of CNS metastases

Patient with an active infection

Patient presenting with cardiac disorders

Any previous treatment with an investigational agent or chemotherapy or biological agent within four weeks prior to baseline.

Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer